BGC > Product Search > Olmutinib | 1353550-13-6

Molecular Formula: C26H26N6O2S
Molecular Weight: 486.58864

Molecular Formula: C26H26N6O2S
Molecular Weight: 486.58864

Description :
Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).

• Molecular Weight :486.18
• Purity :> 98%

Molecular Formula :
C26H26N6O2S
Canonical SMILES :
C=CC(NC1=CC=CC(OC2=C3C(C=CS3)=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1)=O
InChI :
1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
InChIKey :
FDMQDKQUTRLUBU-UHFFFAOYSA-N
Solubility :
DMSO 97 mg/mL (199.34 mM)
Appearance :
Light yellow solid powder
Synonyms :
N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; HM61713; HM 61713; HM-61713; BI 1482694; BI-1482694; BI1482694; Olmutinib

More details are to be found here